Incyte | INCY - Pre Tax Profit

Stock Price
94.10
Daily Change
-1.09 -1.15%
Monthly
-2.91%
Yearly
44.10%
Q2 Forecast
93.39

Incyte reported $343.6M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agenus USD -10.61M 263.52M Dec/2025
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Exelixis USD 267.69M 15M Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Moderna USD -799M 612M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 802M Mar/2026
Novartis USD 5.17B 637M Sep/2025
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026